Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells?

Laura G. Rico; Jordi Juncà; Mike D. Ward; Jolene Bradford; Jordi Petriz

doi:10.18632/oncotarget.12497

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:2335.

Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells?

Laura G. Rico, Jordi Juncà, Mike D. Ward, Jolene Bradford and Jordi Petriz _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:72057-72066. https://doi.org/10.18632/oncotarget.12497

Metrics: PDF 1734 views | HTML 3281 views | ?

Abstract

Laura G. Rico1, Jordi Juncà1, Mike D. Ward2, Jolene Bradford2, Jordi Petriz1

1Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Spain

2Thermo Fisher Scientific, Eugene, Oregon, USA

Correspondence to:

Jordi Petriz, email: [email protected]

Keywords: alkaline phosphatase, stem cells, leukemic stem cells, CD34, Vybrant DyeCycle Violet

Received: July 20, 2016 Accepted: September 29, 2016 Published: October 06, 2016

ABSTRACT

With the aim to detect candidate malignant primitive progenitor populations, we modified an original alkaline phosphatase (ALP) stem cell detection method based on the identification of alkaline phosphatase fluorescent cells in combination with flow cytometry immunophenotyping. Over a period of one year, we have been using this technique to study its activity in patients with leukemia and lymphoma, showing that changes in the alkaline phosphatase levels can be used to detect rare populations of highly refractory malignant cells. By screening different blood cancers, we have observed that this activity is not always restricted to CD34+ leukemic cells, and can be overexpressed in CD34 negative leukemia. We have verified that this method gives accurate and reproducible measurements and our preliminary results suggest that CD34+/ALP^high cells appear to sustain leukemogenesis over time.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12497

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Is alkaline phosphatase the smoking gun for highly refractory primitive leukemic cells?

Abstract